| ?? |
?? ?? |
CAS |
MF |
 |
Tacedinaline |
112522-64-2 |
C15H15N3O2 |
 |
Entinostat |
209783-80-2 |
C21H20N4O3 |
 |
Vorinostat |
149647-78-9 |
C14H20N2O3 |
 |
???????? |
1716-12-7 |
C10H13NaO2 |
 |
????? |
414864-00-9 |
C15H14N2O4S |
![N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide](/CAS/GIF/726169-73-9.gif) |
N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide |
726169-73-9 |
C23H20N6O |
 |
Panobinostat |
404950-80-7 |
C21H23N3O2 |
![(S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate](/CAS/GIF/1268524-70-4.gif) |
(S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate |
1268524-70-4 |
C23H25ClN4O2S |
 |
6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE |
49843-98-3 |
C13H13ClN2O |
 |
SIRTINOL |
410536-97-9 |
C26H22N2O2 |
 |
SRT1720 |
1001645-58-4 |
C25H24ClN7OS |
 |
Lomeguatrib |
192441-08-0 |
C10H8BrN5OS |
 |
ZEBULARINE |
3690-10-6 |
C9H12N2O5 |
 |
RVX-208 |
1044870-39-4 |
C20H22N2O5 |
 |
I-BET151 (GSK1210151A) |
1300031-49-5 |
C23H21N5O3 |
![(2R,3R,4S,5R)-2-(6-aMino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]iMidazol-2-yl)ethyl)cyclobutyl)(isopropyl)aMino)Methyl)tetrahydrofuran-3,4-diol](/CAS/20150408/GIF/1380288-87-8.gif) |
(2R,3R,4S,5R)-2-(6-aMino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]iMidazol-2-yl)ethyl)cyclobutyl)(isopropyl)aMino)Methyl)tetrahydrofuran-3,4-diol |
1380288-87-8 |
C30H42N8O3 |
 |
S)-1-(sec-butyl)-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-3-Methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxaMide |
1346574-57-9 |
C31H38N6O2 |
 |
CUDC-101 |
1012054-59-9 |
C24H26N4O4 |
 |
6-pentadecylsalicylic acid |
16611-84-0 |
C22H36O3 |
 |
MC1568 |
852475-26-4 |
C17H15FN2O3 |
 |
1-Cyclopentyl-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-6-(4-(MorpholinoMethyl)phenyl)-1H-indazole-4-carboxaMide |
1396772-26-1 |
C32H37N5O3 |
 |
UNC 1999 |
1431612-23-5 |
C33H43N7O2 |
 |
UNC 0631 |
1320288-19-4 |
C37H61N7O2 |
 |
5-Carboxy-8-hydroxyquinoline |
5852-78-8 |
C10H7NO3 |
 |
M344 |
251456-60-7 |
C16H25N3O3 |
 |
RG108 |
48208-26-0 |
C19H14N2O4 |
 |
CRA-02478 |
783355-60-2 |
C21H23N3O5 |
 |
MS436 |
1395084-25-9 |
C18H17N5O3S |
![2-Propenamide, N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-](/CAS/GIF/404951-53-7.gif) |
2-Propenamide, N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- |
404951-53-7 |
C22H25N3O3 |
 |
PFI-1 |
1403764-72-6 |
C16H17N3O4S |
 |
SP2509 |
1423715-09-6 |
C19H20ClN3O5S |
![(1S,4Z,7S,10S,11E,20R)-4-ethylidene-7,20-dipropan-2-yl-9-oxa-15,16-dit hia-3,6,18,21-tetrazabicyclo[8.7.6]tricos-11-ene-2,5,8,19,22-pentone](/CAS/GIF/128517-07-7.gif) |
(1S,4Z,7S,10S,11E,20R)-4-ethylidene-7,20-dipropan-2-yl-9-oxa-15,16-dit hia-3,6,18,21-tetrazabicyclo[8.7.6]tricos-11-ene-2,5,8,19,22-pentone |
128517-07-7 |
C24H36N4O6S2 |
 |
Pracinostat |
929016-96-6 |
C20H30N4O2 |
 |
4SC-201 |
864814-88-0 |
C16H19N3O4S |
 |
JNJ-26481585 |
875320-29-9 |
C21H26N6O2 |
 |
GSK 525762A |
1260907-17-2 |
C22H22ClN5O2 |
 |
PI3K/HDAC Inhibitor |
1339928-25-4 |
C23H24N8O4S |
 |
SGI-1027 |
1020149-73-8 |
C27H23N7O |
 |
OTX015 |
202590-98-5 |
C25H22ClN5O2S |
 |
SPLITOMICIN |
5690-03-9 |
C13H10O2 |
 |
PCI 34051 |
950762-95-5 |
C17H16N2O3 |
 |
JIB-04 |
199596-05-9 |
C17H13ClN4 |
 |
GSK 343 |
1346704-33-3 |
C31H39N7O2 |
 |
SGC-CBP30 |
1613695-14-9 |
C28H33ClN4O3 |
 |
BroMosporine |
1619994-69-2 |
C17H20N6O4S |
 |
SCRIPTAID |
287383-59-9 |
C18H18N2O4 |
 |
tasquinimod |
254964-60-8 |
C20H17F3N2O4 |
 |
GSK J4 HCl |
1373423-53-0 |
C24H27N5O2 |
 |
UNC-1215 |
1415800-43-9 |
C32H43N5O2 |
 |
AR-42 |
935881-37-1 |
C18H20N2O3 |
 |
ACY-1215 |
1316214-52-4 |
C24H27N5O3 |
 |
Tazemetostat (EPZ-6438) |
1403254-99-8 |
C34H44N4O4 |
 |
EPZ004777 |
1338466-77-5 |
C28H41N7O4 |
 |
UNC 669 |
1314241-44-5 |
C15H20BrN3O |
 |
RGFP 109 |
1215493-56-3 |
C20H25N3O2 |
 |
BRD4770 |
1374601-40-7 |
C25H23N3O3 |
 |
EPZ015666 |
1616391-65-1 |
C20H25N5O3 |
 |
ITF2357 |
732302-99-7 |
C24H30ClN3O5 |
![3-Cyclopentene-1,2-diol, 5-(4-aMino-1H-iMidazo[4,5-c]pyridin-1-yl)-3-(hydroxyMethyl)-, (Hydrochloride) (1:1), (1S,2R,5R)-](/CAS/GIF/120964-45-6.gif) |
3-Cyclopentene-1,2-diol, 5-(4-aMino-1H-iMidazo[4,5-c]pyridin-1-yl)-3-(hydroxyMethyl)-, (Hydrochloride) (1:1), (1S,2R,5R)- |
120964-45-6 |
C12H15ClN4O3 |
 |
OG-L002 |
1357302-64-7 |
C15H15NO |
 |
OF-1 |
919973-83-4 |
C17H18BrN3O4S |
 |
??????? |
99873-43-5 |
C11H14ClNO3 |
 |
LMK-235 |
1418033-25-6 |
C15H22N2O4 |
 |
4SC-202(?????) |
910462-43-0 |
C23H21N5O3S |
 |
RGFP966 |
1396841-57-8 |
C21H19FN4O |
 |
ReModelin hydrobroMide |
1622921-15-6 |
C15H15BrN4S |
 |
Tubacin |
537049-40-4 |
C41H43N3O7S |
 |
SRT2104 (GSK2245840) |
1093403-33-8 |
C26H24N6O2S2 |
 |
SGC0946 |
1561178-17-3 |
C28H40BrN7O4 |
 |
Tubastatin-A |
1252003-15-8 |
C20H21N3O2 |
 |
MM-102 |
1417329-24-8 |
C35H49F2N7O4 |
![2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide](/CAS/GIF/304896-28-4.gif) |
2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide |
304896-28-4 |
C23H13Cl2N3O2 |
 |
MI-2 (Menin-MLL Inhibitor) |
1271738-62-5 |
C18H25N5S2 |
 |
CAY10603 |
1045792-66-2 |
C22H30N4O6 |
 |
MI-3 (Menin-MLL Inhibitor) |
1271738-59-0 |
C18H25N5S2 |
 |
CPI-203 |
1446144-04-2 |
C19H18ClN5OS |
 |
EI1 |
1418308-27-6 |
C23H26N4O2 |
 |
Nexturastat A |
1403783-31-2 |
C19H23N3O3 |
 |
C 646 |
328968-36-1 |
C24H19N3O6 |
 |
GSK1324726A (I-BET726) |
1300031-52-0 |
C25H23ClN2O3 |
 |
PFI3 |
1819363-80-8 |
C19H19N3O2 |
 |
PFI-2 |
1627676-59-8 |
C23H25F4N3O3S |
 |
MG149 |
1243583-85-8 |
C22H28O3 |
 |
CAY10683 (SantacruzaMate A) |
1477949-42-0 |
C15H22N2O3 |
 |
ML234 |
1222800-79-4 |
C21H23N3O2 |
 |
TMP269 |
1314890-29-3 |
C25H21F3N4O3S |
 |
HPOB |
1429651-50-2 |
C17H18N2O4 |
 |
BRD73954 |
1440209-96-0 |
C16H16N2O3 |
 |
BIX 01294 |
1392399-03-9 |
C28H41Cl3N6O2 |
 |
UNC0379 |
1620401-82-2 |
C23H35N5O2 |
 |
GSK-LSD1 |
1431368-48-7 |
C14H20N2 |